MedPath

Fundación Canaria de Investigación Sanitaria

🇪🇸Spain
Ownership
Private
Established
2014-01-01
Employees
-
Market Cap
-
Website
http://www.funcanis.org

Clinical Trials

4

Active:0
Completed:1

Trial Phases

3 Phases

Phase 2:1
Phase 4:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (33.3%)
Phase 2
1 (33.3%)
Phase 4
1 (33.3%)

3D Decision Support Tool for Brain Tumour Surgery Development and Validation: Observational Study

Not yet recruiting
Conditions
Brain (Nervous System) Cancers
Brain Tumor, Primary
First Posted Date
2025-06-25
Last Posted Date
2025-06-25
Lead Sponsor
Fundación Canaria de Investigación Sanitaria
Target Recruit Count
320
Registration Number
NCT07036783

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

Phase 4
Recruiting
Conditions
Kidney Transplant Failure and Rejection
Interventions
Drug: Normal Treatment
First Posted Date
2021-06-23
Last Posted Date
2023-12-05
Lead Sponsor
Fundación Canaria de Investigación Sanitaria
Target Recruit Count
80
Registration Number
NCT04936282
Locations
🇪🇸

Hospital Universitario de Canarias, Tenerife, None Selected, Spain

🇪🇸

Fundación Puigvert, Barcelona, Spain

🇪🇸

Hospital Universitari Valld´Hebron, Barcelona, Spain

and more 1 locations

Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer

Phase 2
Conditions
Prostate Carcinoma
Interventions
First Posted Date
2017-06-22
Last Posted Date
2018-01-18
Lead Sponsor
Fundación Canaria de Investigación Sanitaria
Target Recruit Count
70
Registration Number
NCT03196388
Locations
🇪🇸

Hospital Ramón y Cajal, Madrid, Spain

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.